Skip to main content
Premium Trial:

Request an Annual Quote

R Scott Greer, Lutz Lingnau, James Glynn, Rich Schifreen

Premium

Sirna Therapeutics said this week that R Scott Greer has been named chairman of the company's board of directors.

Greer, currently a member of Sirna's board, is also chairman of the boards of Abgenix, a company he founded, and Acologix.

He is also managing director of Numenor Ventures.

Sirna also said this week that Lutz Lingnau has joined the company's board.

Lingnau was a member of the executive board of Schering, and was also president and CEO of Berlex Laboratories, Schering's US drugs group. Sirna President and CEO Howard Robin was previously corporate vice president and general manager at Berlex.


Invitrogen said this week that James Glynn will retire as director of the company at its annual stockholders meeting on April 21 after seven years in the role.

Glynn joined Invitrogen's board of directors in 1998, and has held various positions at the company including CFO and interim CEO.

Upon his retirement, Invitrogen's board will be reduced in size from 10 directors to nine.


Rich Schifreen, vice president of research products at Mirus, has been appointed to the board of Platypus Technologies, a developer of nanotechnologies for the life sciences.

The Scan

Gone, But Now Reconstructed SARS-CoV-2 Genomes

In a preprint, a researcher describes his recovery of viral sequences that had been removed from a common database.

Rare Heart Inflammation Warning

The Food and Drug Administration is adding a warning about links between a rare inflammatory heart condition and two SARS-CoV-2 vaccines, Reuters reports.

Sandwich Sampling

The New York Times sent tuna sandwiches for PCR analysis.

Nature Papers Describe Gut Viruses, New Format for Storing Quantitative Genomic Data, More

In Nature this week: catalog of DNA viruses of the human gut microbiome, new dense depth data dump format to store quantitative genomic data, and more.